January 31, 2015 3:34 AM ET

Biotechnology

Company Overview of Prosensa Holding N.V.

Company Overview

Prosensa Holding N.V., a biotechnology company, engages in the discovery and development of ribonucleic acid-modulating therapeutics for the treatment of genetic disorders. The company’s products focus on the treatment of neuromuscular and neurodegenerative disorders, including duchenne muscular dystrophy (DMD), myotonic dystrophy, and huntington’s diseases. It develops drisapersen, which is in Phase III studies to restore dystrophin expression and enhancing muscle condition; PRO044 that is in Phase I/II studies to address a separate sub-population of DMD patients; and PRO045, PRO053, PRO052, and PRO055 to address other distinct sub-populations of DMD patients. The company also develops PRO1...

J.H. Oortweg 21

Leiden,  2333 CH

Netherlands

Founded in 1997

89 Employees

Phone:

31 71 332 2100

Fax:

31 71 332 2088

Key Executives for Prosensa Holding N.V.

Prosensa Holding N.V. does not have any Key Executives recorded.

Prosensa Holding N.V. Key Developments

Prosensa Holding N.V., Special/Extraordinary Shareholders Meeting, Jan 13, 2015

Prosensa Holding N.V., Special/Extraordinary Shareholders Meeting, Jan 13, 2015., at 14:00 Central European Standard Time. Location: The offices of company, J.H. Oortweg 21. Agenda: To consider the regarding the recommended tender offer of BioMarin Falcons B.V. and one or more of its affiliates for all the outstanding ordinary shares with a nominal value of €0.01 in the share capital of the company, in exchange for (i) $17.75 per share, net to the seller in cash, without interest and less any applicable withholding taxes, plus (ii) one non-transferrable contingent value right, which represents the contractual right to receive cash payments of up to $4.14 per Share in aggregate, without interest and less any applicable withholding taxes, upon the achievement of certain product approval milestones with respect to the commercialization of drisapersen within certain time periods; to consider the discharge of the current managing Directors; to consider the appointment and reappointment of the Directors; to consider the discharge of the resigning Supervisory Directors; to consider the appointment and reappointment of the Directors; and to consider other issues.

BioMarin Pharmaceutical Inc., Prosensa Holding N.V. - M&A Call

To discuss the definitive agreement in which BioMarin Pharmaceutical Inc. will offer to purchase all of the outstanding ordinary shares of Prosensa Holding N.V

Prosensa Holding N.V. Reports Consolidated Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Provides Cash and Cash Equivalents Guidance for December 31, 2014

Prosensa Holding N.V. reported consolidated unaudited earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported operating loss was €10.522 million compared with €4.282 million for the same period last year. Net loss was €10.649 million or €0.29 basic and diluted per share compared with €4.293 million or €0.12 basic and diluted per share for the same period last year. For the nine months, the company reported total revenue was €14.755 million compared with €6.763 million for the same period last year. Operating loss was €11.166 million compared with €12.334 million for the same period last year. Net loss was €11.320 million or €0.31 basic and diluted per share compared with €12.452 million or €0.40 basic and diluted per share for the same period last year. The company expect that cash and cash equivalents as of December 31, 2014 will range from 52 million to 54 million. This guidance does not account for the impact of any future acquisitions, dispositions, partnerships, license transactions or changes to the company's capital structure, including future securities offerings.

Similar Private Companies By Industry

Company Name Region
Lelystad Biologicals B.V. Europe
Immuno Valley Europe
Millipore Ireland B.V. Europe
Target Quest, B.V. Europe
Applikon Biotechnology B.V. Europe

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
November 24, 2014
--
Private Placement
August 11, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Prosensa Holding N.V., please visit www.prosensa.eu. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.